Skip to main content

Advertisement

Log in

Hormones as doping in sports

  • Review
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Though we may still sing today, as did Pindar in his eighth Olympian Victory Ode, “… of no contest greater than Olympia, Mother of Games, gold-wreathed Olympia…”, we must sadly admit that today, besides blatant over-commercialization, there is no more ominous threat to the Olympic games than doping. Drug-use methods are steadily becoming more sophisticated and ever harder to detect, increasingly demanding the use of complex analytical procedures of biotechnology and molecular medicine. Special emphasis is thus given to anabolic androgenic steroids, recombinant growth hormone and erythropoietin as well as to gene doping, the newly developed mode of hormones abuse which, for its detection, necessitates high-tech methodology but also multidisciplinary individual measures incorporating educational and psychological methods. In this Olympic year, the present review offers an update on the current technologically advanced endocrine methods of doping while outlining the latest procedures applied—including both the successes and pitfalls of proteomics and metabolomics—to detect doping while contributing to combating this scourge.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. D.H. Catlin, T.H. Murray, Performance-enhancing drugs, fair competition, and Olympic sport. J. Am. Med. Assoc. 276(3), 231–237 (1996)

    Article  CAS  Google Scholar 

  2. L.H. Duntas, C. Parisis, Doping: a challenge to the endocrinologist. A reappraisal in view of the Olympic games of 2004. Hormones (Athens) 2(1), 35–42 (2003)

    Google Scholar 

  3. P.L. Toutain, Veterinary medicines and competition animals: the question of medication versus doping control. Handb. Exp. Pharmacol. 199, 315–339 (2010)

    Article  PubMed  CAS  Google Scholar 

  4. H.M. Prendergast, T. Bannen, T.B. Erickson, K.R. Honore, The toxic torch of the modern Olympic games. Vet. Hum. Toxicol. 45(2), 97–102 (2003)

    PubMed  Google Scholar 

  5. M. Thevis, P. Hemmersbach, H. Geyer, W. Schänzer, Doping in disabled sports. Doping control activities at the Paralympic games 1984–2008 and in Germany 1992–2008. Med. Klin. (Munich) 104(12), 918–924 (2009)

    Article  CAS  Google Scholar 

  6. M. Thevis, T. Kuuranne, H. Geyer, W. Schänzer, Annual banned-substance review: analytical approaches in human sports drug testing. Drug Test Anal. 4(1), 2–16 (2012)

    Article  PubMed  CAS  Google Scholar 

  7. M. Kamber, Development of the role of national anti-doping organisations in the fight against doping: from past to future. Forensic Sci. Int. 213(1–3), 3–9 (2011)

    Article  PubMed  Google Scholar 

  8. L. Di Luigi, F. Romanelli, P. Sgrò, A. Lenzi, Andrological aspects of physical exercise and sport medicine. Endocrine 59(6):503–508 [Epub ahead of print] (2012)

    Google Scholar 

  9. C. Saudan, N. Baume, N. Robinson, L. Avois, P. Mangin, M. Saugy, Testosterone and doping control. Br. J. Sports Med. 40, i21–i24 (2006)

    Article  PubMed  Google Scholar 

  10. E.T. Keller, W.B. Ershler, C. Chang, The androgen receptor: a mediator of diverse responses. Front. Biosci. 1(1), d59–d71 (1996)

    PubMed  CAS  Google Scholar 

  11. C.A. Heinlein, C. Chang, Androgen receptor (AR) coregulators: an overview. Endocr. Rev. 23(2), 175–200 (2002)

    Article  PubMed  CAS  Google Scholar 

  12. A.B. Cadwallaber, C.S. Lim, D.E. Rollins, F. Botrè, The androgen receptor and its use in biological assays: looking toward effect-based testing and its applications. J. Anal. Toxicol. 35(9), 594–607 (2011)

    Article  Google Scholar 

  13. F. Sjöqvist, M. Garle, A. Rane, Use of doping agents, particularly anabolic steroids, in sports and society. Lancet 371(9627), 1872–1882 (2008)

    Article  PubMed  CAS  Google Scholar 

  14. NIDA, National Institute on Drug Abuse Research Report Series: Anabolic Steroid Abuse (NIDA, Bethesda, 2006)

    Google Scholar 

  15. C.J. Bagatell, W.J. Bremner, Androgens in men—uses and abuses. N. Engl. J. Med. 334(11), 707–714 (1996)

    Article  PubMed  CAS  Google Scholar 

  16. R.C. Hall, R.C. Hall, Abuse of supraphysiologic doses of anabolic steroids. South. Med. J. 98(5), 550–555 (2005)

    Article  PubMed  Google Scholar 

  17. F. Hartgens, H. Kuipers, Effects of androgenic–anabolic steroids in athletes. Sports Med. 34(8), 513–554 (2004)

    Article  PubMed  Google Scholar 

  18. A.H. Beckett, D.A. Cowan, Misuse of drugs in sport. Br. J. Sports Med. 12(4), 185–194 (1978)

    Article  PubMed  CAS  Google Scholar 

  19. O.J. Pozo, P. Van Eenoo, K. Deventer, L. Lootens, S. Grimalt, J.V. Sancho, F. Hernández, P. Meuleman, G. Leroux-Roels, F.T. Delbeke, Detection and structural investigation of metabolites of stanozolol in human urine by liquid chromatography tandem mass spectrometry. Steroids 74(10–11), 837–852 (2009)

    PubMed  CAS  Google Scholar 

  20. A. Brinkmann, G.G. Kuiper, W. de Boer, E. Mulder, J. Bolt, G.J. Van Steenbrugge, H.J. van der Molen, Characterization of androgen receptors after photoaffinity labelling with [3H]methyltrienolone (R1881). J. Steroid Biochem. 24(1), 245–249 (1986)

    Article  PubMed  CAS  Google Scholar 

  21. L.M. Irving, M. Wall, D. Neumark-Sztainer, M. Story, Steroid use among adolescents: findings from project EAT. J. Adolesc. Health 30(4), 243–252 (2002)

    Article  PubMed  Google Scholar 

  22. G. Kanayama, J.I. Hudson, H.G. Jr, Pope, long-term psychiatric and medical consequences of anabolic–androgenic steroid abuse: a looming public health concern? Drug Alcohol Depend. 98(1–2), 1–12 (2008)

    Article  PubMed  CAS  Google Scholar 

  23. T.A. Pagonis, N.V. Angelopoulos, G.N. Koukoulis, C.S. Hadjichristodoulou, Psychiatric side effects induced by supraphysiological doses of combinations of anabolic steroids correlate to the severity of abuse. Eur. Psychiatry 21(8), 551–562 (2006)

    Article  PubMed  Google Scholar 

  24. M. Montisci, R. El Mazloum, G. Cecchetto, C. Terranova, S.D. Ferrara, G. Thiene, C. Basso, Anabolic androgenic steroids abuse and cardiac death in athletes: morphological and toxicological findings in four fatal cases. Forensic Sci. Int. 217(1–3), e13–e18 (2012)

    Article  PubMed  CAS  Google Scholar 

  25. G. Lippi, G. Banfi, Doping and thrombosis in sports. Semin. Thromb. Hemost. 37(8), 918–928 (2011)

    Article  PubMed  CAS  Google Scholar 

  26. U. Mareck, H. Geyer, G. Opfermann, M. Thevis, W. Schänzer, Factors influencing the steroid profile in doping control analysis. J. Mass Spectrom. 43(7), 877–891 (2008)

    Article  PubMed  CAS  Google Scholar 

  27. J.P. Danaceau, M.S. Morrison, M.H. Slawson, Quantitative confirmation of testosterone and epitestosterone in human urine by LC/Q-ToF mass spectrometry for doping control. J. Mass Spectrom. 43(7), 993–1000 (2008)

    Article  PubMed  CAS  Google Scholar 

  28. B. Maralikova, W. Weinmann, Confirmatory analysis for drugs of abuse in plasma and urine by high-performance liquid chromatography-tandem mass spectrometry with respect to criteria for compound identification. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 811(1), 21–30 (2004)

    PubMed  CAS  Google Scholar 

  29. R. Aguilera, C.K. Hatton, D.H. Catlin, Detection of epitestosterone doping by isotope ratio mass spectrometry. Clin Chem. 48(4), 629–636 (2002)

    PubMed  CAS  Google Scholar 

  30. I. Athanasiadou, Y.S. Angelis, E. Lyris, A. Vonaparti, N.S. Thomaidis, M.A. Koupparis, C. Georgakopoulos, Two-step derivatization procedures for the ionization enhancement of anabolic steroids in LC–ESI–MS for doping control analysis. Bioanalysis 4(2), 167–175 (2012)

    Article  PubMed  CAS  Google Scholar 

  31. M. Thevis, A. Thomas, M. Kohler, S. Beuck, I. Möller, M. Schäfer, G. Rodchenkov, S. Yin, J.A. Loo, H. Geyer, W. Schänzer, Mass spectrometry-based characterization of new drugs and methods of performance manipulation in doping control analysis. Eur. J. Mass Spectrom. 16(3), 301–312 (2010)

    Article  CAS  Google Scholar 

  32. H.M. Pereira, M.C. Padilha, F.R. Neto, Tetrahydrogestrinone analysis and designer steroids revisited. Bioanalysis 1(8), 1475–1489 (2009)

    Article  PubMed  CAS  Google Scholar 

  33. P. Teale, J. Scarth, S. Hudson, Impact of the emergence of designer drugs upon sports doping testing. Bioanalysis 4(1), 71–88 (2012)

    Article  PubMed  CAS  Google Scholar 

  34. M.K. Parr, G. Opfermann, H. Geyer, F. Westphal, F.D. Sönnichsen, J. Zapp, D. Kwiatkowska, W. Schänzer, Seized designer supplement named “1-androsterone”: identification as 3β-hydroxy-5α-androst-1-en-17-one and its urinary elimination. Steroids 76(6), 540–547 (2011)

    Article  PubMed  CAS  Google Scholar 

  35. C. Gómez, O.J. Pozo, H. Geyer, J. Marcos, M. Thevis, W. Schänzer, J. Segura, R. Ventura, New potential markers for the detection of boldenone misuse. Steroid Biochem. Mol. Biol. 132(3–5):239–246 (2012) [Epub ahead of print]

    Google Scholar 

  36. S. Guddat, G. Fußhöller, H. Geyer, A. Thomas, H. Braun, N. Haenelt, A. Schwenke, C. Klose, M. Thevis, W. Schänzer, Clenbuterol: regional food contamination a possible source for inadvertent doping in sports. Drug Test Anal. 4(6), 534–538 (2012)

    Article  PubMed  CAS  Google Scholar 

  37. E. Strahm, P.E. Sottas, C. Schweizer, M. Saugy, J. Dvorak, C. Saudan, Steroid profiles of professional soccer players: an international comparative study. Br. J. Sports Med. 43(14), 1126–1130 (2009)

    Article  PubMed  CAS  Google Scholar 

  38. J.J. Schulze, J. Lundmark, M. Garle, I. Skilving, L. Ekström, A. Rane, Doping test results dependent on genotype of uridine diphospho-glucuronosyl transferase 2B17, the major enzyme for testosterone glucuronidation. J. Clin. Endocrinol. Metab. 93(7), 2500–2506 (2008)

    Article  PubMed  CAS  Google Scholar 

  39. A. Rane, L. Ekström, Androgens and doping tests: genetic variation and pit-falls. Br. J. Clin. Pharmacol. 74(1), 3–15 (2012)

    Article  PubMed  CAS  Google Scholar 

  40. J.J. Schulze, J. Lundmark, M. Garle, L. Ekström, P.E. Sottas, A. Rane, Substantial advantage of a combined Bayesian and genotyping approach in testosterone doping tests. Steroids 74(3), 365–368 (2009)

    Article  PubMed  CAS  Google Scholar 

  41. C. Quan, F. Su, H. Wang, H. Li, Development of anabolic–androgenic steroids purity certified reference materials for anti-doping. Steroids 76(14), 1527–1534 (2011)

    Article  PubMed  CAS  Google Scholar 

  42. J.C. Rijk, A. Lommen, M.L. Essers, M.J. Groot, J.M. Van Hende, T.G. Doeswijk, M.W. Nielen, Metabolomics approach to anabolic steroid urine profiling of bovines treated with prohormones. Anal. Chem. 81(16), 6879–6888 (2009)

    Article  PubMed  CAS  Google Scholar 

  43. K.K. Ho, Diagnosis and management of adult growth hormone deficiency. Endocrine 12(2), 189–196 (2000)

    Article  PubMed  CAS  Google Scholar 

  44. J. Gibney, J.D. Wallace, T. Spinks, L. Schnorr, A. Lanicar, R.C. Cuneo, S. Lockhart, K.G. Burnand, F. Salomon, P.H. Sonksen, D. Russell-Jones, The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. J. Clin. Endocrinol. Metab. 84(8), 2596–2602 (1999)

    Article  PubMed  CAS  Google Scholar 

  45. G. Götherström, B.A. Bengtsson, I. Bosaeus, G. Johansson, J. Svensson, A 10-year, prospective study of the metabolic effects of growth hormone replacement in adults. J. Clin. Endocrinol. Metab. 92(4), 1442–1445 (2007)

    Article  PubMed  CAS  Google Scholar 

  46. W.M. Widdowson, J. Gibney, The effect of growth hormone replacement on exercise capacity in patients with GH deficiency: a metaanalysis. J. Clin. Endocrinol. Metab. 93(11), 4413–4417 (2008)

    Article  PubMed  CAS  Google Scholar 

  47. W.M. Widdowson, J. Gibney, The effect of growth hormone (GH) replacement on muscle strength in patients with GH-deficiency: a meta-analysis. Clin. Endocrinol. (Oxf) 72(6), 787–792 (2010)

    Article  CAS  Google Scholar 

  48. M. Gola, S. Bonadonna, M. Doga, A. Giustina, Clinical review: growth hormone and cardiovascular risk factors. J. Clin. Endocrinol. Metab. 90(3), 1864–1870 (2005)

    Article  PubMed  CAS  Google Scholar 

  49. H. Liu, D.M. Bravata, I. Olkin, A. Friedlander, V. Liu, B. Roberts, E. Bendand, O. Saynina, S.R. Salpeter, A.M. Garber, A.R. Hoffman, Systematic review: the effects of growth hormone on athletic performance. Ann. Intern. Med. 148(10), 747–758 (2008)

    PubMed  Google Scholar 

  50. K.E. Yarasheski, J.J. Zachweija, T.J. Angelopoulos, D.M. Bier, Short-term growth hormone treatment does not increase muscle protein synthesis in experienced weight lifters. J. Appl. Physiol. 74(6), 3073–3076 (1993)

    PubMed  CAS  Google Scholar 

  51. A.L. Carrel, D.B. Allen, Effects of growth hormone on body composition and bone metabolism. Endocrine 12(2), 163–172 (2000)

    Article  PubMed  CAS  Google Scholar 

  52. V. Birzniece, U.J. Meinhart, M.A. Umpleby, D.J. Hanlesman, K.K. Ho, Interaction between testosterone and growth hormone on whole-body protein anabolism occurs in the liver. J. Clin. Endocrinol. Metab. 96(4), 1060–1067 (2011)

    Article  PubMed  CAS  Google Scholar 

  53. V. Birzniece, A.E. Nelson, K.K. Ho, Growth hormone administration: is it safe and effective for athletic performance. Endocrinol. Metab. Clin. North Am. 39(1), 11–23 (2010)

    Article  PubMed  CAS  Google Scholar 

  54. A. Berggren, C. Ehrnborg, T. Rosén, L. Ellegård, B.A. Bengtsson, K. Caidahl, Short-term administration of supraphysiological recombinant human growth hormone (GH) does not increase maximum endurance exercise capacity in healthy, active young men and women with normal GH-insulin-like growth factor I axes. J. Clin. Endocrinol. Metab. 90(6), 3268–3273 (2005)

    Article  PubMed  CAS  Google Scholar 

  55. U. Meinhardt, A.E. Nelson, J.L. Hansen, V. Birniece, D. Clifford, K.C. Leung, K. Graham, K.K. Ho, The effects of growth hormone on body composition and physical performance in recreational athletes: a randomized trial. Ann. Int. Med. 152(9), 568–577 (2010)

    PubMed  Google Scholar 

  56. S. Longobardi, N. Keay, C. Ehrnborg, A. Cittadini, T. Rosén, R. Dall, M.A. Boroujerdi, E.E. Basset, M.L. Healy, C. Pentecost, J.D. Wallace, J. Powrie, J.O. Jorgensen, L. Saccà, Growth hormone (GH) effects on bone and collagen turnover in healthy adults and its potential as a marker of GH abuse in sports: a double blind, placebo-controlled study. The GH-2000 study group. J. Clin. Endocrinol. Metab. 85(4), 1505–1512 (2000)

    Article  PubMed  CAS  Google Scholar 

  57. M. Volterrani, P. Desenzani, R. Lorusso, A. d’Aloia, F. Manelli, A. Giustina, Haemodynamic effects of intravenous growth hormone in congestive heart failure. Lancet 349(9058), 1067–1068 (1997)

    Article  PubMed  CAS  Google Scholar 

  58. M. Saugy, N. Robinson, C. Saudan, N. Baume, L. Avois, P. Mangin, Human growth hormone doping in sport. Br. J. Sports Med. 40(Suppl 1), i35–i39 (2006)

    Article  PubMed  Google Scholar 

  59. K.K. Ho, A.E. Nelson, Growth hormone in sports: detecting the doped or duped. Horm. Res. Paediatr. 76(Suppl 1), 84–90 (2011)

    Article  PubMed  CAS  Google Scholar 

  60. I. Erotokritou-Mulligan, N. Guha, M. Stow, E.E. Bassett, C. Bartlett, D.A. Cowan, P.H. Sönksen, R.I. Holt, The development of decision limits for the implementation of the GH-2000 detection methodology using current commercial insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays. Growth Horm. IGF Res. 22(2), 53–58 (2012)

    Article  PubMed  CAS  Google Scholar 

  61. L. Di Luigi, A.E. Rigamonti, F. Agosti, M. Mencarelli, P. Sgrò, N. Marazzi, S.G. Cella, E.E. Müller, A. Sartorio, Combined evaluation of resting IGF1, N-terminal propeptide of type III procollagen and C-terminal cross-linked telopeptide of type I collagen levels might be useful for detecting inappropriate GH administration in female athletes. Eur. J. Endocrinol. 160(5), 753–758 (2009)

    Article  PubMed  CAS  Google Scholar 

  62. A. Sartorio, F. Agosti, N. Marazzi, N.A. Maffiuletti, S.G. Cella, A.E. Rigamonti, L. Guidetti, L. Di Luigi, E.E. Müller, Combined evaluation of resting IGF-I, N-terminal propeptide of type III procollagen (PIIINP) and C-terminal cross-linked telopeptide of type I collagen (ICTP) levels might be useful for detecting inappropriate GH administration in athletes: a preliminary report. Clin Endocrinol (Oxf) 61(4), 487–493 (2004)

    Article  CAS  Google Scholar 

  63. J.D. Wallace, R.C. Cuneo, M. Bidlingmaier, P.A. Lundberg, L. Carlsson, C.L. Boguszewski, J. Hay, M.L. Healy, R. Napoli, R. Dall, T. Rosén, C.J. Strasburger, The response of molecular isoforms of growth hormone to acute exercise in trained adult males. J. Clin. Endocrinol. Metab. 86(1), 200–206 (2001)

    Article  PubMed  CAS  Google Scholar 

  64. J.D. Wallace, R.C. Cuneo, M. Bidlingmaier, P.A. Lundberg, L. Carlsson, C.L. Boguszewski, J. Hay, M. Boroujerdi, A. Cittadini, R. Dall, T. Rosén, C.J. Strasburger, Changes in non-22-kilodalton (kDa) isoforms of growth hormone (GH) after administration of 22-kDa recombinant human GH in trained adult males. J. Clin. Endocrinol. Metab. 86(4), 1731–1737 (2001)

    Article  PubMed  CAS  Google Scholar 

  65. M. Bidlingmaier, Z. Wu, C.J. Strasburger, Test method: GH. Baillieres. Best Pract. Res. Clin. Endocrinol. Metab. 14(1), 99–109 (2000)

    Article  CAS  Google Scholar 

  66. M. Irie, M. Ueki, Y. Kishikawa, M. Nishii, M. Kawahara, 20 K-GH and its use in detecting GH abuse. Growth Horm. IGF Res. 19(4), 352–356 (2009)

    Article  PubMed  CAS  Google Scholar 

  67. A. Keller, Z. Wu, J. Kratzsch, E. Keller, W.F. Blum, A. Kniess, R. Preiss, J. Teichert, C.J. Strasburger, M. Bidlingmaier, Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration. Eur. J. Endocrinol. 156(6), 647–653 (2007)

    Article  PubMed  CAS  Google Scholar 

  68. O. Barroso, P. Schamasch, O. Rabin, Detection of GH abuse in sport: past, present and future. Growth Horm. IGF Res. 19(4), 369–374 (2009)

    Article  PubMed  CAS  Google Scholar 

  69. N. Guha, I. Erotokritou-Mulligan, C. Bartlett, A.D. Cowan, E.E. Bassett, M. Stow, P.H. Sönksen, R.I. Holt, The effects of a freeze-thaw cycle and pre-analytical storage temperature on the stability of insulin-like growth factor-I and pro-collagen type III N-terminal propeptide concentrations: implications for the detection of growth hormone misuse in athletes. Drug Test Anal. 4(6), 455–459 (2012)

    Article  PubMed  CAS  Google Scholar 

  70. I. Erotokritou-Mulligan, E. Basset, D.A. Cowan, C. Bartlett, P. Milward, A. Sartorio, P.H. Sönksen, R.I. Holt, The use of growth hormone (GH)-dependent markers in the detection of GH abuse in sport: physiological intra-individual variation of IGF-I, type 3 pro-collagen (P-III-P) and the GH-2000 detection score. Clin. Endocrinol. (Oxf.) 72(4), 520–526 (2010)

    Article  CAS  Google Scholar 

  71. G. Such-Sanmartín, J. Bosch, J. Segura, R. Gutiérrez-Gallego, Growth hormone abuse and biological passport: is mannan-binding lectin a complementary candidate? Clin. J. Sport Med. 21(5), 441–443 (2011)

    Article  PubMed  Google Scholar 

  72. N. Guha, I. Erotokritou-Mulligan, C. Burford, G. Stobridge, J. Brigg, T. Drake, E.E. Basset, D. Cowan, C. Bartlett, P.H. Sönksen, R.I. Holt, Serum insulin-like growth factor-I and pro-collagen type III N-terminal peptide in adolescent elite athletes: implications for the detection of growth hormone abuse in sport. J. Clin. Endocinol. Metab. 95(6), 2969–2976 (2010)

    Article  CAS  Google Scholar 

  73. A.E. Nelson, U. Meinhardt, J.L. Hansen, I.H. Walker, G. Stone, C.J. Howe, K.C. Leung, M.J. Siebel, R.C. Baxter, D.J. Handelsman, R. Kazlauskas, K.K. Ho, Pharmacodynamics of growth hormone abuse biomarkers and the influence of gender and testosterone: a randomized double-blind placebo-controlled study in young recreational athletes. J. Clin. Endocrinol. Metab. 93(6), 2213–2222 (2008)

    Article  PubMed  CAS  Google Scholar 

  74. C.J. Mitchell, A.E. Nelson, M.J. Cowley, W. Kaplan, G. Stone, S.K. Sutton, A. Lau, C.M. Lee, K.K. Ho, Detection of growth hormone doping by gene expression profiling of peripheral blood. J. Clin. Endocrinol. Metab. 94(12), 4703–4709 (2009)

    Article  PubMed  CAS  Google Scholar 

  75. J. Ding, E.O. List, S. Okada, J.J. Kopchick, Perspective: proteomic approach to detect biomarkers of human growth hormone. Growth Horm. IGF Res. 19(4), 399–407 (2009)

    Article  PubMed  CAS  Google Scholar 

  76. A. Thomas, M. Kohler, W. Schänzer, P. Delahaut, M. Thevis, Determination of IGF-1 and IGF-2, their degradation products and synthetic analogues in urine by LC–MS/MS. Analyst 136(5), 1003–1012 (2011)

    Article  PubMed  CAS  Google Scholar 

  77. F. Boyard-Kieken, G. Dervilly-Pinel, P. Garcia, A.C. Paris, M.A. Popot, B. le Bizec, Y. Bonnaire, Comparison of different liquid chromatography stationary phases in LC-HRMS metabolomics for the detection of recombinant growth hormone doping control. J. Sep. Sci. 34(24), 3493–3501 (2011)

    Article  PubMed  CAS  Google Scholar 

  78. J.M.J. García, E.T. Sánchez, D.O. Hidalgo, E.A. Conejo, Erythropoietin pharmacology. Clin. Transl. Oncol. 9(11), 715–722 (2007)

    Article  CAS  Google Scholar 

  79. R.L. Wilber, Detection of DNA-recombinant human epoetin-alfa as a pharmacological ergogenic aid. Sports Med. 32(2), 125–142 (2002)

    Article  PubMed  Google Scholar 

  80. W. Jelkmann, Use of recombinant human erythropoietin as an antianemic and performance enhancing drug. Curr. Pharm. Biotechnol. 1(1), 11–31 (2000)

    Article  PubMed  CAS  Google Scholar 

  81. J. Mørkeberg, Detection of autologous blood transfusions in athletes: a historical perspective. Transfus. Med. Rev. 26(3), 199–208 (2012)

    Article  PubMed  Google Scholar 

  82. S. Giraud, N. Robinson, P. Mangin, M. Saugy, Scientific and forensic standards for homologous blood transfusion anti-doping analyses. Forensic Sci. Int. 179(1), 22–33 (2012)

    Google Scholar 

  83. S. Elliott, E. Pham, I.C. Macdougall, Erythropoietins: a common mechanism of action. Exp. Haematol. 36(12), 1573–1584 (2008)

    Article  CAS  Google Scholar 

  84. J.M. Topf, CERA: third-generation erythropoiesis-stimulating agent. Expert Opin. Pharmacother. 9(5), 839–849 (2008)

    Article  PubMed  CAS  Google Scholar 

  85. G. Lippi, M. Franchini, G.L. Salvagno, G.C. Guidi, Biochemistry, physiology, and complications of blood doping: facts and speculation. Crit. Rev. Clin. Lab. Sci. 43(4), 349–391 (2006)

    Article  PubMed  CAS  Google Scholar 

  86. M. Tsivou, H.A. Dimopoulou, I.P. Leontiou, D.G. Georgakopoulos, M.A. Koupparis, J. Atta-Politou, C.G. Georgakopoulos, Stabilization of human urine doping control samples: III. Recombinant human erythropoietin. Clin. Chim. Acta. 411(5–6), 448–452 (2010)

    Article  PubMed  CAS  Google Scholar 

  87. J.A. Pascual, V. Belalcazar, C. de Bolos, R. Gutiérrez, E. Llop, J. Segura, Recombinant erythropoietin and analogues: a challenge for doping control. Ther. Drug Monit. 26(2), 175–179 (2004)

    Article  PubMed  CAS  Google Scholar 

  88. E. Diamanti-Kandarakis, P.A. Konstantinopoulos, J. Papailiou, S.A. Kandarakis, A. Andreopoulos, G.P. Sykiotis, Erythropoietin abuse and erythropoietin gene doping: detection strategies in the genomic era. Sports Med. 35(10), 831–840 (2005)

    Article  PubMed  Google Scholar 

  89. C. Lundby, P. Robach, B. Saltin, The evolving science of detection of ‘blood doping’. Br. J. Pharmacol. 165(5), 1306–1315 (2012)

    Article  PubMed  CAS  Google Scholar 

  90. C. Reichel, The overlooked difference between human endogenous and recombinant erythropoietins and its implication for sports drug testing and pharmaceutical drug design. Drug Test Anal. 3(11–12), 883–891 (2011)

    Article  PubMed  CAS  Google Scholar 

  91. C. Reichel, SARCOSYL-PAGE: a new electrophoretic method for the separation and immunological detection of PEGylated proteins. Methods Mol. Biol. 865, 65–79 (2012)

    Article  CAS  Google Scholar 

  92. C. Reichel, M. Thevis, Detection of EPO-Fc fusion protein in human blood: screening and confirmation protocols for sports drug testing. Drug Test Anal. doi:10.1002/dta.1381 (2012) [Epub ahead of print]

  93. M. Lönnberg, M. Andrén, G. Birgegård, M. Drevin, M. Garle, J. Carlson, Rapid detection of erythropoiesis-stimulating agents in urine and serum. Anal. Biochem. 420(2), 101–114 (2012)

    Article  PubMed  CAS  Google Scholar 

  94. C. Reichel, OMICS-strategies and methods in the fight against doping. Forensic Sci. Int. 213(1–3), 20–34 (2011)

    Article  PubMed  CAS  Google Scholar 

  95. H. Schwarzenbach, Impact of physical activity and doping on epigenetic gene regulation. Drug Test Anal. 3(10), 682–687 (2011)

    Article  PubMed  CAS  Google Scholar 

  96. WADA, The 2008 Prohibited List (WADA, Montreal, 2008)

    Google Scholar 

  97. C.F. Argüelles, E. Hernández-Zamora, Gene doping: gene transfer and possible molecular detection. Gac. Med. Mex. 143(2), 169–172 (2007)

    PubMed  Google Scholar 

  98. R.S. Oliveira, T.F. Collares, K.R. Smith, T.V. Collares, F.K. Seixas, The use of genes for performance enhancement: doping or therapy? Braz. J. Med. Biol. Res. 44(12), 1194–1201 (2011)

    Article  PubMed  CAS  Google Scholar 

  99. H.E. Montgomery, R. Marshall, H. Hemingway, S. Myerson, P. Clarkson, C. Dollery, M. Hayward, D.E. Holliman, M. Jubb, M. World, E.L. Thomas, A.E. Brynes, N. Saeed, M. Barnard, J.D. Bell, K. Prasad, M. Rayson, P.J. Talmud, S.E. Humphries, Human gene for physical performance. Nature 393(6682), 221–222 (1998)

    Article  PubMed  CAS  Google Scholar 

  100. N.C. Sharp, The human genome and sport, including epigenetics, gene doping, and athleticogenomics. Endocrinol. Metab. Clin. North Am. 39(1), 201–215 (2010)

    Article  PubMed  CAS  Google Scholar 

  101. E.W.Neuberger, M. Jurkiewicz, D.A. Moser, P. Simon, Detection of EPO gene doping in blood. Drug Test Anal. doi:10.1002/dta.1347 (2012) [Epub ahead of print]

  102. A. Baoutina, I.E. Alexander, J.E. Rasko, K.R. Emslie, Potential use of gene transfer in athletic performance enhancement. Mol. Ther. 15(10), 1751–1766 (2007)

    Article  PubMed  CAS  Google Scholar 

  103. M.M. Mansour, H.M. Azzazy, The hunt for gene dopers. Drug Test Anal. 1(7), 311–322 (2009)

    Article  PubMed  CAS  Google Scholar 

  104. W. Ni, C. Le Guiner, P. Moullier, R.O. Snyder, Development and utility of an internal threshold control (ITC) real-time PCR assay for exogenous DNA detection. PLoS One 7(5), e36461 (2012) [Epub ahead of print]

  105. C. D’Angelo, C. Tamburrini, Addict to win? A different approach to doping. J. Med. Ethics 36(11), 700–707 (2010)

    Article  PubMed  Google Scholar 

  106. G. Lippi, G. Banfi, M. Franchini, G.C. Guidi, New strategies for doping control. J. Sports Sci. 26(5), 441–445 (2008)

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

There is no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Leonidas H. Duntas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Duntas, L.H., Popovic, V. Hormones as doping in sports. Endocrine 43, 303–313 (2013). https://doi.org/10.1007/s12020-012-9794-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-012-9794-9

Keywords

Navigation